Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
We are excited to share with you more videos from a recent series of discussions between Drs. Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services at City of Hope Comprehensive Cancer Center, and Founder, President and CEO Of GRACE, Charu Aggarwal, MD, MPH with the Perelman Center for Advanced Medicine, University of Pennsylvania, and Benjamin Levy MD, Clinical Director Of Medical Oncology, Assistant Professor Of Oncology at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital.
The doctors recently collaborated from their respective geographical locations to review top discussion points from Lung Cancer from ASCO 2019. In this video, the doctors discuss their Lurbinectedin and if it is promising for relapsed sclc.
To join the conversation, visit https://cancergrace.org/forum.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...
Recent Comments
That's…